COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children.

Publication date: Apr 01, 2024

Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.

Concepts Keywords
Inflammatory Acceptability
Nct04826588 Acceptance
Parents Children
Swiss Covid
Vaccinated Inflammatory
Limited
Mis
Multisystem
Parents
Sars
Syndrome
Vaccinated
Vaccination
Vaccine

Semantics

Type Source Name
disease VO COVID-19 vaccine
disease MESH Multisystem Inflammatory Syndrome in Children
disease MESH syndrome
drug DRUGBANK Methylprednisolone
disease VO vaccination
disease VO vaccinated
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)